Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Esler

Showing results (71-80 of 132) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Pharmacology & Physiology|March 1, 2008
Single-unit sympathetic discharge pattern in pathological conditions associated with elevated cardiovascular riskElisabeth Lambert, Tye Dawood, Markus Schlaich, et al.
Hypertension (Dallas, Tex. : 1979)|September 27, 2006
Mechanisms of sympathetic activation in obesity-related hypertensionMurray Esler, Nora Straznicky, Nina Eikelis, et al.
Journal of Hypertension|March 21, 2020
Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertensionMurray Esler, Gavin Lambert, Danielle Esler, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|February 8, 2002
The influence of aging on the human sympathetic nervous system and brain norepinephrine turnoverMurray Esler, Jacqueline Hastings, Gavin Lambert, et al.
Biogerontology|May 17, 2002
Influence of ageing on the sympathetic nervous system and adrenal medulla at rest and during stressMurray Esler, Gavin Lambert, David Kaye, et al.
Hypertension (Dallas, Tex. : 1979)|November 22, 2017
Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?Murray Esler, Gavin Lambert, Markus Schlaich, et al.
Journal of Hypertension|July 24, 2019
Consequences of the evolutionary cardiovascular challenge of human bipedalism: orthostatic intolerance syndromes, orthostatic hypertensionMurray Esler, Stevo Julius, Benjamin Coghlan, et al.
Pharmacogenetics|July 2, 2003
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failureDavid M Kaye, Belinda Smirk, Carolyn Williams, et al.
Blood Pressure|August 27, 2022
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justifiedMurray Esler, Sverre E Kjeldsen, Atul Pathak, et al.
Hypertension (Dallas, Tex. : 1979)|April 5, 2022
Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension GuidelinesGiuseppe Mancia, Sverre E Kjeldsen, Reinhold Kreutz, et al.
Pageof 14

Showing results (71-80 of 132) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Pharmacology & Physiology|March 1, 2008
Single-unit sympathetic discharge pattern in pathological conditions associated with elevated cardiovascular riskElisabeth Lambert, Tye Dawood, Markus Schlaich, et al.
Hypertension (Dallas, Tex. : 1979)|September 27, 2006
Mechanisms of sympathetic activation in obesity-related hypertensionMurray Esler, Nora Straznicky, Nina Eikelis, et al.
Journal of Hypertension|March 21, 2020
Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertensionMurray Esler, Gavin Lambert, Danielle Esler, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|February 8, 2002
The influence of aging on the human sympathetic nervous system and brain norepinephrine turnoverMurray Esler, Jacqueline Hastings, Gavin Lambert, et al.
Biogerontology|May 17, 2002
Influence of ageing on the sympathetic nervous system and adrenal medulla at rest and during stressMurray Esler, Gavin Lambert, David Kaye, et al.
Hypertension (Dallas, Tex. : 1979)|November 22, 2017
Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?Murray Esler, Gavin Lambert, Markus Schlaich, et al.
Journal of Hypertension|July 24, 2019
Consequences of the evolutionary cardiovascular challenge of human bipedalism: orthostatic intolerance syndromes, orthostatic hypertensionMurray Esler, Stevo Julius, Benjamin Coghlan, et al.
Pharmacogenetics|July 2, 2003
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failureDavid M Kaye, Belinda Smirk, Carolyn Williams, et al.
Blood Pressure|August 27, 2022
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justifiedMurray Esler, Sverre E Kjeldsen, Atul Pathak, et al.
Hypertension (Dallas, Tex. : 1979)|April 5, 2022
Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension GuidelinesGiuseppe Mancia, Sverre E Kjeldsen, Reinhold Kreutz, et al.
Pageof 14